Member news

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

More at immutep.com…

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

More at curevac.com…

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

More at curevac.com…

Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer

More at epigenomics.com…

Evotec and EQRx announce integrated drug discovery and development partnership

More at evotec.com…

c-LEcta expands product range to include additional enzyme NuCLEANase®

More at c-lecta.com…

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

More at pieris.com…

InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

More at inflarx.de…

Medigene provides Q3 2021 update

More at medigene.com…

Evotec SE reports results for the first nine months 2021 and provides corporate update

More at evotec.com…

MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results

More at morphosys.com…

MorphoSys Announces Departure of Roland Wandeler

More at morphosys.com…

CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

More at curevac.com…

Epigenomics AG veröffentlicht Finanzergebnisse für die ersten neun Monate 2021

More at irpages2.eqs.com…

PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2021

More at paion.com…

Evotec reaches programme designations in neuroscience collaboration with Bristol Myers Squibb

More at evotec.com…

Deutsche Messe founds the creative network "MEDIA FACTORY"

More at messe.de…

Data validating TCR-Ts targeted to ovarian tumor-specific "dark matter" antigen to be presented at SITC

More at medigene.com…

Evotec SE announces closing of public offering

More at evotec.com…

MetrioPharm Signs European Commission Grant Agreement for €7.9 Million

4SC – More than 80% of events now reached for unblinding of RESMAIN

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer

Evotec and EQRx announce integrated drug discovery and development partnership

c-LEcta expands product range to include additional enzyme NuCLEANase®

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Medigene provides Q3 2021 update

Evotec SE reports results for the first nine months 2021 and provides corporate update

MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results

MorphoSys Announces Departure of Roland Wandeler

CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

Epigenomics AG veröffentlicht Finanzergebnisse für die ersten neun Monate 2021

PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2021

Evotec reaches programme designations in neuroscience collaboration with Bristol Myers Squibb

Deutsche Messe founds the creative network "MEDIA FACTORY"

Data validating TCR-Ts targeted to ovarian tumor-specific "dark matter" antigen to be presented at SITC

Evotec SE announces closing of public offering